Adjuvant treatment with tamoxifen. Recruitment into studies assessing optimum duration of treatment must continue

BMJ. 1996 Apr 20;312(7037):1036-7. doi: 10.1136/bmj.312.7037.1036b.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antineoplastic Agents, Hormonal / adverse effects*
  • Breast Neoplasms / drug therapy*
  • Chemotherapy, Adjuvant
  • Clinical Trials as Topic*
  • Female
  • Humans
  • Tamoxifen / adverse effects*
  • Time Factors

Substances

  • Antineoplastic Agents, Hormonal
  • Tamoxifen